Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists
摘要:
Hit-to-lead optimization of a HTS hit led to new carbamoyloxime derivatives. After identification of an advanced hit (8d) the CYP enzyme inhibitory activity of this class of compounds was successfully eliminated. Systematic exploration of different parts of the advanced hit led us to some promising lead compounds with mGluR5 affinities comparable to that of MPEP. (C) 2010 Elsevier Ltd. All rights reserved.
This invention is directed to a tetrahydro-cyclopentyl pyrazole cannabinoid modulator compound of formula (I):
and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.
This invention is directed to a tetrahydro-cyclopentyl pyrazole cannabinoid modulator compound of formula (I):
and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease.
[EN] TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS<br/>[FR] MODULATEURS CANNABINOÏDES DE TYPE TÉTRAHYDROCYCLOPENTYLPYRAZOLE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2007035945A1
公开(公告)日:2007-03-29
[EN] This invention is directed to a tetrahydro-cyclopentyl pyrazole cannabinoid modulator compound of formula (I): and a method for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease. [FR] La présente invention concerne un modulateur cannabinoïde de type tétrahydrocyclopentylpyrazole de formule (I) : ainsi qu'une méthode d'emploi dans le traitement, le soulagement ou la prévention d'un syndrome, d'un trouble ou d'une maladie faisant intervenir un récepteur cannabinoïde.